HIJRA, BETWEEN SOCIOLOGICAL AND THEOLOGICAL PHENOMENON by Firmansyah Firmansyah

Subjects: Get full text

De l’étiquette à la marque : la labellisation comme unificateur des projets territoriaux ? by Valia Filloz, Valérie Colomb

Subjects: Get full text

How to Handle Data Imbalance and Feature Selection Problems in CNN-Based Stock Price Forecasting by Zinnet Duygu Aksehir, Erdal Kilic

Subjects: Get full text

Réactions sociales face aux comportements déviants : problèmes de théorie et de méthode [1962] by John I. Kitsuse

Subjects: Get full text

Nutritional content and healthiness in sweet and salty snacks and beverages popular in South Korea and the United States assessed by nutrition labels: a cross-sectional comparative study by Bo Jeong Gong, Segovia Lucas, Diewo Camara, Pauline E. Jolly, Chandrika Piyathilake, Taisun Hyun

Subjects: “…nutrition labeling…”
Get full text

Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trialResearch in context by Abha A. Gupta, Anna Tinker, Derek Jonker, Rahma Jamal, Hal Hirte, Eric W. Winquist, Quincy Chu, Christian Kollmannsberger, Ralph Wong, Thierry Alcindor, Torsten O. Nielsen, Ming Tsao, Tricia R. Cottrell, Diane Provencher, John Hilton, Monika K. Krzyżanowska, Christine Elser, Sebastien Hotte, Joana Sederias, Siwei Zhang, Wei Tu, Janet Dancey

“…Methods: We designed a multi-centre, non-blinded, open-label phase II basket trial with each of the following 8 rare cancers considered a separate phase II trial: salivary carcinoma, carcinoma of unknown primary (CUP) with tumour infiltrating lymphocytes and/or expressing PD-L1, mucosal melanoma, acral melanoma, osteosarcoma, undifferentiated pleomorphic sarcoma, clear cell carcinoma of the ovary (CCCO) or squamous cell carcinoma of the anal canal (SCCA). …”
Get full text

Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab by Elaine M. Jagoda PhD, Olga Vasalatiy PhD, Falguni Basuli PhD, Ana Christina L. Opina PhD, Mark R. Williams BS, Karen Wong MS, Kelly C. Lane BS, Steve Adler PhD, Anita Thein Ton MS, Lawrence P. Szajek PhD, Biying Xu PhD, Donna Butcher BS, Elijah F. Edmondson DVM, PhD, Rolf E. Swenson PhD, John Greiner PhD, James Gulley MD, PhD, Janet Eary MD, Peter L. Choyke MD

“…Objective: The goal is to evaluate avelumab, an anti-PD-L1 monoclonal immunoglobulin G antibody labeled with zirconium-89 in human PD-L1-expressing cancer cells and mouse xenografts for clinical translation. …”
Get full text

Efficacy and Safety of Sacubitril/Valsartan Versus Amlodipine in Japanese Patients With Essential Hypertension: A Randomized, Multicenter, Open‐Label, Noninferiority Study (PARASOL Study) by Koichi Yamamoto, Daisuke Yarimizu, Ayano Shimanishi, Shunsuke Eguchi, Kazuma Iekushi, Yoichi Takami, Yoichi Nozato, Kazuomi Kario, Hiromi Rakugi

“…However, there has been no available evidence on the comparison between sacubitril/valsartan and calcium channel blockers (CCBs), a well‐established class of antihypertensive drugs. In this open‐label, multicenter study, we aimed to demonstrate the efficacy and safety of sacubitril/valsartan versus amlodipine, one of the most widely used CCBs, after 8 weeks of treatment. …”
Get full text

Indications for an antidepressive effect of thymosin alpha-1 in a small open-label proof of concept study in common variable immune deficiency patients with depression by Daniël G. Aynekulu Mersha, Sarah E. Fromme, Frank van Boven, Gara Arteaga-Henríquez, Annemarie Wijkhuijs, Marianne van der Ent, Raf Berghmans, Bernard T. Baune, Hemmo A. Drexhage, Virgil Dalm

“…Objective: To treat CVID patients with a comorbid depressive episode with Tα1 to increase naïve T cells and thereby improve mood. Design: A small open-label, proof of concept trial. Five depressed CVID patients (Hamilton Depression Rating Scale, HDRS >12) could be treated with Tα1 (8 weeks, 1.6 mg daily subcutaneously, 1st week, thereafter 1.6 mg twice weekly). …”
Get full text

Metformin Treatment in Type 2 Diabetes in Pregnancy: An Active Controlled, Parallel-Group, Randomized, Open Label Study in Patients with Type 2 Diabetes in Pregnancy by Jahan Ara Ainuddin, Nasim Karim, Sidra Zaheer, Syed Sanwer Ali, Anjum Ara Hasan

“…In this randomized, open label study, 206 patients with type 2 diabetes in pregnancy who met the eligibility criteria were selected from the antenatal clinics. …”
Get full text

Therapeutic Management of a Substantial Pelvic Aneurysmatic Bone Cyst Including the Off-Label Use of Denosumab in a 35-Year-Old Female Patient by D. Ntalos, M. Priemel, C. Schlickewei, D. M. Thiesen, J. M. Rueger, A. S. Spiro

Get full text

Growth Phase-Dependent Proteomes of the Malaysian Isolated Lactococcus lactis Dairy Strain M4 Using Label-Free Qualitative Shotgun Proteomics Analysis by Theresa Wan Chen Yap, Amir Rabu, Farah Diba Abu Bakar, Raha Abdul Rahim, Nor Muhammad Mahadi, Rosli Md. Illias, Abdul Munir Abdul Murad

Get full text

An open-label study to determine the maximum tolerated dose of oral ESK-440 administered as a single agent in patients with advanced or metastatic solid tumors by Russell J. Schilder, Drew Rasco, Manish R. Sharma

“…Methods: This phase 1, open-label, dose-finding study evaluated the maximum tolerated dose (MTD), safety, efficacy, and pharmacokinetics of ESK-440 in participants with advanced or metastatic solid tumors (ClinicalTrials.gov: NCT01922752). …”
Get full text

Perioperative tislelizumab plus chemotherapy for locally advanced gastroesophageal junction adenocarcinoma (NEOSUMMIT-03): a prospective, nonrandomized, open-label, phase 2 trial by Run-Cong Nie, Shu-Qiang Yuan, Ya Ding, Yong-Ming Chen, Yuan-Fang Li, Cheng-Cai Liang, Mu-Yan Cai, Guo-Ming Chen, Wei Wang, Xiao-Wei Sun, De-Sheng Weng, Dan-Dan Li, Jing-Jing Zhao, Xiao-Jiang Chen, Yuan-Xiang Guan, Zhi-Min Liu, Yao Liang, Ma Luo, Jun Chi, Hai-Bo Qiu, Zhi-Wei Zhou, Xiao-Shi Zhang, Ying-Bo Chen

“…Abstract This prospective, nonrandomized, open-label phase 2 trial (Chinese Clinical Trial Registry, ChiCTR2200061906) aimed to evaluate the effectiveness of adding the PD-1 antibody tislelizumab to perioperative chemotherapy in patients with locally advanced gastroesophageal junction adenocarcinoma (GEJA). …”
Get full text

Combination of Single-Photon Emission Computed Tomography and Magnetic Resonance Imaging to Track In-Oxine–Labeled Human Mesenchymal Stem Cells in Neuroblastoma-Bearing Mice by Lorena Cussó, Isabel Mirones, Santiago Peña-Zalbidea, Verónica García-Vázquez, Javier García-Castro, Manuel Desco

“…In conclusion, tracking 111 In-labeled hMSCs combining SPECT and MRI is feasible and may be transferable to clinical research. …”
Get full text

Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial by Graham McIlroy, Charlotte Gaskell, Aimee Jackson, Emily Yafai, Rachel Tasker, Catherine Thomas, Sonia Fox, Rebecca Boucher, Fitsum Ghebretinsea, Claire Harrison, Adam J. Mead, Mary Frances McMullin

“…Methods FEDORA is a single arm, multicentre, open-label, Bayesian phase II trial to assess tolerability, safety, and activity of fedratinib with ropeginterferon alfa-2b aiming to recruit 30 patients. …”
Get full text

Efficacy of Cabbage Leaf versus Cooling Gel Pad or Diclofenac Gel for Patients with Knee Osteoarthritis: A Randomized Open-Labeled Controlled Clinical Trial by Thanapon Chobpenthai, Patcharapol Arunwatthanangkul, Wiriya Mahikul

Get full text

Proximity Labeling-Based Identification of MGAT3 Substrates and Revelation of the Tumor-Suppressive Role of Bisecting GlcNAc in Breast Cancer via GLA Degradation by Bowen Wang, Xin He, Yue Zhou, Zengqi Tan, Xiang Li, Feng Guan, Lei Lei

Subjects: Get full text

S-Adenosyl-L-Methionine Augmentation in Patients with Stage II Treatment-Resistant Major Depressive Disorder: An Open Label, Fixed Dose, Single-Blind Study by Domenico De Berardis, Stefano Marini, Nicola Serroni, Gabriella Rapini, Felice Iasevoli, Alessandro Valchera, Maria Signorelli, Eugenio Aguglia, Giampaolo Perna, Anatolia Salone, Giuseppe Di Iorio, Giovanni Martinotti, Massimo Di Giannantonio

Get full text

A multicenter, randomized, open label, two formulation, crossover bioequivalence trial of doxorubicin hydrochloride liposomal injection in Chinese patients with metastatic breast cancer by Jingshu Wang, Xiuping Lai, Herui Yao, Hui Yang, Xiaolong Cao, Xiaochen Wang, Ying Wang, Weiqi Nian, Xiaodong Zheng, Qingxiu Mai, Anding Liu, Xiaozhi Lv, Xiaoying Bi, Junyi Chen, Junyan Wu, Suiwen Ye

“…Methods To achieve these goals, the trial employed a randomized, open-label, two-formulation crossover dosing strategy among Chinese patients with metastatic breast cancer. …”
Get full text